| Budget Amount *help |
¥25,350,000 (Direct Cost: ¥19,500,000、Indirect Cost: ¥5,850,000)
Fiscal Year 2019: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
Fiscal Year 2018: ¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
Fiscal Year 2017: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
|
|---|
| Outline of Final Research Achievements |
Tumor-specific genetic changes (mutation, deletion, translocation) and specific miRNA expression were analyzed by next-generation sequence analysis (NGS) using cell-free nucleic acids (cell-free DNA and microRNA) derived from plasma samples of approximately 200 children with solid malignant tumors. These patients were treated in Hiroshima University Hospital and whose tumor and plasma samples were simultaneously stored. As genetic alterations, MYCN amplification and ALK mutations in neuroblastoma, and CTNNB1 abnormalities in hepatoblastoma were detected. In neuroblastoma, three miRNAs associated with malignancy (miR-375, miR-92a-3p and miR-99a-5p) were also identified. From these results, it was considered that the NGS analysis method using cell-free nucleic acid and miRNA could be available for a bedside cancer fluid biopsy method that is highly reliable and minimally invasive in children.
|
